Loading
VBC103 is an experimental drug designed to recognize two proteins on cancer cells. Its early trial is testing safety and activity.
NCT07299747 registers a first-in-human phase I/IIa study of VBC103 targeting Nectin-4 and TROP2. It includes dose escalation, dose optimization and cohort expansion in advanced solid tumors. The registry names VelaVigo Bio Inc as sponsor. No tabular results are posted. Payload identity and comparative clinical efficacy are not inferred from the public registry.
1.VBC103's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VBC103" OR ABSTRACT:"VBC103") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VBC103, not a curated reading list.
Shares Nectin-4, Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/